50790-30-2

Basic information

• Product Name: N-(3-CYANOPHENYL)METHANESULFONAMIDE
• Synonyms: 3-(Methanesulfonylamino)benzonitrile
• CAS NO: 50790-30-2
• Molecular Formula: C₈H₈N₂O₂S
• Molecular Weight: 196.23
• Mol File: 50790-30-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 343°C at 760 mmHg
• Flash Point: 161.2°C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 7.26E-05mmHg at 25°C
• Refractive Index: 1.587
• CAS DataBase Reference: N-(3-CYANOPHENYL)METHANESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-CYANOPHENYL)METHANESULFONAMIDE(50790-30-2)
• EPA Substance Registry System: N-(3-CYANOPHENYL)METHANESULFONAMIDE(50790-30-2)

Safety Data

• Hazardous Substances Data: 50790-30-2(Hazardous Substances Data)

Usage

General Description

N-(3-Cyanophenyl)methanesulfonamide is a chemical compound with the formula C8H8N2O2S. It is a white solid that is soluble in organic solvents but insoluble in water. N-(3-CYANOPHENYL)METHANESULFONAMIDE is commonly used as a reagent in organic synthesis, particularly in the formation and modification of carbon-carbon and carbon-nitrogen bonds. It is also employed in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical compounds. Additionally, N-(3-Cyanophenyl)methanesulfonamide has been studied for its potential biological activities, including its antimicrobial and antitumor properties, making it a subject of interest in medicinal chemistry research.

InChI:InChI=1/C8H8N2O2S/c1-13(11,12)10-8-4-2-3-7(5-8)6-9/h2-5,10H,1H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 2237-30-1 m-cyanoaniline 

Downstream Products

• 1089581-43-0 C₁₅H₁₄N₂O₂S 
• 597561-37-0 N-(3-cyanophenyl)-N-methylmethanesulfonamide 
• 869371-36-8 N-(3-(aminomethyl)phenyl)-N-methylmethanesulfonamide 
• 2307461-45-4 C₂₅H₂₈F₃N₅O₆S 

Relevant articles and documents

BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE

The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

HETEROARYL-PYRAZOLE DERIVATIVE

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.